Journal of Clinical Oncology, Vol 12, 1156-1163, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma

V Rusch, L Saltz, E Venkatraman, R Ginsberg, P McCormack, M Burt, M Markman and D Kelsen
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

PURPOSE: This study investigated the feasibility of a novel approach to the treatment of malignant pleural mesothelioma by combining surgical resection with immediate postoperative intrapleural chemotherapy and subsequent systemic chemotherapy. PATIENTS AND METHODS: Patients with biopsy-proven, resectable malignant pleural mesothelioma underwent pleurectomy/decortication immediately followed by intrapleural chemotherapy with cisplatin 100 mg/m2 and mitomycin 8 mg/m2. Systemic chemotherapy was started 3 to 5 weeks postoperatively and included cisplatin 50 mg/m2 on days 1, 8, 15, 22, 36, 43, 50, and 57, and mitomycin 8 mg/m2 on days 1 and 36. Patients were then monitored by serial chest and abdominal computed tomographic (CT) scans every 3 months until death or for a minimum of 18 months, whichever occurred first. RESULTS: Of 36 patients entered onto the study, 28 had pleurectomy/decortication and intrapleural chemotherapy. There was one postoperative death, and two episodes of grade 4 renal toxicity after intrapleural chemotherapy. The 23 patients who also had systemic chemotherapy received a median of 80% and 87% of the planned total cisplatin and mitomycin doses, respectively. No grade 3 or 4 toxicities were observed. The overall survival rate of the 27 patients who were originally candidates for systemic chemotherapy was 68% at 1 year and 40% at 2 years, with a median survival duration of 17 months. Locoregional disease was the most common form of relapse (16 of 20 patients). CONCLUSION: This short but aggressive combined modality regimen was generally well tolerated, but should not be used outside of a protocol setting because of the potential for serious toxicity. Overall survival was as good or better than with previously reported multimodality approaches, but other strategies are needed to improve local control.

This article has been cited by other articles:

				R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. S. Bains, and V. W. Rusch Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 620 - 626. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				I. Opitz, D. Lardinois, S. Arni, S. Hillinger, P. Vogt, B. Odermatt, V. Rousson, and W. Weder Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 772 - 778. [Abstract] [Full Text] [PDF]

				V. W. Rusch Editorial comment: A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 534 - 535. [Full Text] [PDF]

				P. S. Adusumilli, M.-K. Chan, M. Hezel, Z. Yu, B. M. Stiles, T.-C. Chou, V. W. Rusch, and Y. Fong Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma Ann. Surg. Oncol., January 1, 2007; 14(1): 258 - 269. [Abstract] [Full Text] [PDF]

				W. G. Richards, L. Zellos, R. Bueno, M. T. Jaklitsch, P. A. Janne, L. R. Chirieac, B. Y. Yeap, R. J. Dekkers, P. M. Hartigan, L. Capalbo, et al. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma J. Clin. Oncol., April 1, 2006; 24(10): 1561 - 1567. [Abstract] [Full Text] [PDF]

				Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 697 - 703.e3.

				C. Lu, R. Perez-Soler, B. Piperdi, G. L. Walsh, S. G. Swisher, W. R. Smythe, H. J. Shin, J. Y. Ro, L. Feng, M. Truong, et al. Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., May 20, 2005; 23(15): 3495 - 3501. [Abstract] [Full Text] [PDF]

				M. Pistolesi and J. Rusthoven Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies Chest, October 1, 2004; 126(4): 1318 - 1329. [Abstract] [Full Text] [PDF]

				D. J. Stewart, A. Martin-Ucar, J. E. Pilling, J. G. Edwards, K. J. O'Byrne, and D. A. Waller The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma Ann. Thorac. Surg., July 1, 2004; 78(1): 245 - 252. [Abstract] [Full Text] [PDF]

				J. H. Schouwink, L. Schultze Kool, E. J. Rutgers, F. A. N. Zoetmulder, N. van Zandwijk, M. J. v.d. Vijver, and P. Baas The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma Ann. Thorac. Surg., June 1, 2003; 75(6): 1715 - 1718. [Abstract] [Full Text] [PDF]

				W.R. Smythe and P.F. Mansfield Hyperthermia: Has Its Time Come? Ann. Surg. Oncol., April 1, 2003; 10(3): 210 - 212. [Full Text] [PDF]

				S. van Ruth, P. Baas, R.L. M. Haas, E.J. Th. Rutgers, V.J. Verwaal, and F.A. N. Zoetmulder Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma Ann. Surg. Oncol., March 1, 2003; 10(2): 176 - 182. [Abstract] [Full Text] [PDF]

				S. van Ruth, P. Baas, and F. A. N. Zoetmulder Surgical Treatment of Malignant Pleural Mesothelioma: A Review Chest, February 1, 2003; 123(2): 551 - 561. [Abstract] [Full Text] [PDF]

				E. de Bree, S. van Ruth, P. Baas, E. J. Th. Rutgers, N. van Zandwijk, A. J. Witkamp, and F. A. N. Zoetmulder Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy in Patients With Malignant Pleural Mesothelioma or Pleural Metastases of Thymoma Chest, February 1, 2002; 121(2): 480 - 487. [Abstract] [Full Text] [PDF]

				V. W. Rusch, K. Rosenzweig, E. Venkatraman, L. Leon, A. Raben, L. Harrison, M. S. Bains, R. J. Downey, and R. J. Ginsberg A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 788 - 795. [Abstract] [Full Text] [PDF]

				H. Schouwink, E. T. Rutgers, J. van der Sijp, H. Oppelaar, N. van Zandwijk, R. van Veen, S. Burgers, F. A. Stewart, F. Zoetmulder, and P. Baas Intraoperative Photodynamic Therapy After Pleuropneumonectomy in Patients With Malignant Pleural Mesothelioma : Dose Finding and Toxicity Results Chest, October 1, 2001; 120(4): 1167 - 1174. [Abstract] [Full Text] [PDF]

				M.W. Grossebner, A.A. Arifi, M. Goddard, and A.J. Ritchie Mesothelioma - VATS biopsy and lung mobilization improves diagnosis and palliation Eur. J. Cardiothorac. Surg., December 1, 1999; 16(6): 619 - 623. [Abstract] [Full Text] [PDF]

				J. R. Roberts Surgical Treatment of Mesothelioma: Pleurectomy* Chest, December 1, 1999; 116(suppl_3): 446S - 449S. [Abstract] [Full Text] [PDF]

				S. C. Grondin and D. J. Sugarbaker Pleuropneumonectomy in the Treatment of Malignant Pleural Mesothelioma* Chest, December 1, 1999; 116(suppl_3): 450S - 454S. [Abstract] [Full Text] [PDF]

				D. B. Campbell Malignant Mesothelioma Ann. Thorac. Surg., May 1, 1997; 63(5): 1503 - 1505. [Full Text]

				V. W. Rusch and E. Venkatraman THE IMPORTANCE OF SURGICAL STAGING IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 815 - 826. [Abstract] [Full Text]